Key result
First-line combination chemotherapy with docetaxel and doxorubicin achieved an overall response rate of 78.6% in patients with metastatic breast cancer.
Why the study?
Does the combination of docetaxel and doxorubicin provide clinical efficacy and acceptable toxicity as first-line chemotherapy in patients with metastatic breast cancer?
Does the combination of docetaxel and doxorubicin provide clinical efficacy and acceptable toxicity as first-line chemotherapy in patients with metastatic breast cancer?
The combination of docetaxel and doxorubicin is an active first-line regimen for metastatic breast cancer, yielding a high response rate with acceptable toxicity.
May support first-line use in metastatic breast cancer; leaves open randomized confirmation of benefit and safety.
Docetaxel (Taxotere) and doxorubicin have previously demonstrated a significant antitumor activity in patients with metastatic breast cancer. Furthermore, a lack of cross resistance and overlapping toxicities between the two agents have been reported. In a prospective study, docetaxel (80 mg/m2, 1-hr iv infusion) and doxorubicin (60 mg/m2, 1-hr iv infusion) were administered as first-line chemotherapy in metastatic breast cancer patients to evaluate the clinical efficacy and toxicity of the combination. Forty-three patients were enrolled in the study. The median age was 47 years (range, 30-69). The docetaxel-doxorubicin combination was applied with 3-week intervals until progression. Complete response was achieved in 9 (21.4%) of 42 assessable patients and partial response in 24 (57.2%) patients, for an overall response rate of 78.6%. Median response duration was 8 months (3-18 months). Nausea and vomiting (76%), alopecia (64%), neutropenia (35.7%) and mucositis (33%) were the major side effects of the combination. There was one case of cardiac toxicity. In conclusion, the docetaxel-doxorubicin protocol can be considered as an active regimen for the treatment of patients with metastatic breast cancer with acceptable toxicity and a fairly high response rate.
No takes yet. Share an insight, caveat, or question.
Baltalı et al. (2001) studied metastatic breast cancer (n=43). docetaxel and doxorubicin was evaluated on overall response rate. First-line combination chemotherapy with docetaxel and doxorubicin achieved an overall response rate of 78.6% in patients with metastatic breast cancer.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: